{
  "docId": "019dd923-5eff-723e-9be8-8ecf5ec778da",
  "docSlug": "2EobkBpnCoKZCisTIQTA",
  "documentTitle": "Here's the 13-slide pitch deck ReCode Therapeutics used to raise $120 million from OrbiMed and Pfizer to develop new mRNA medicines",
  "authorId": "Pitchdecks",
  "authorName": "ReCode Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.774,
  "pageNumber": 3,
  "pageCount": 13,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a hub-and-spoke diagram to connect the core platform to strategic pillars, followed by a row of key company highlights.",
  "elementsJson": [
    "paragraph",
    "process_diagram",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5eff-723e-9be8-8ecf5ec778da/3",
  "deckHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da",
  "deckJsonHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da.json",
  "deckAnchorHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.34,
        "x": 0.33,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Proprietary Selective Organ Targeting (SORT) LNP platform",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bec70ac1-d8dd-4471-b592-3978bdb3c4dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "list",
      "text": "Strong leadership team with rare disease development experience; Filing INDs for primary ciliary dyskinesia (Q4 '22) & cystic fibrosis (Q2 '23); In-house pipeline focus on genetically-defined orphan diseases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b12b070f-6450-4fb6-a178-40e66787883f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Extrahepatic delivery of diverse genetic cargoes; Modular, with potential to expand to diverse organs and cargoes; Portfolio and Partnering Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b76ffef1-921d-428a-9aaa-d2ee79a174f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.76,
        "y": 0.07
      },
      "kind": "metric",
      "text": "$280M raised with strong investor syndicate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5872132-cfed-4d48-8a40-8856aab90b43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Capital raised: $280M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-9437-76cb-b83a-725f44bce5de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.58,
        "x": 0.35,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Next-generation lipid nanoparticle (LNP) platform company developing genetic therapeutics utilizing mRNA and gene correction",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd885fd2-61c6-403f-a991-9d3905f61655",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.22,
        "x": 0.08,
        "y": 0.06
      },
      "kind": "title",
      "text": "ReCode Therapeutics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a5c2776-671f-44fb-a8bd-fa7ddb847a3e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c2503e2e-877d-4766-b618-a93a6cd1dfe1",
      "evidence": "Strong leadership team with rare disease development experience; Filing INDs for primary ciliary dyskinesia (Q4 '22) & cystic fibrosis (Q2 '23); In-house pipeline focus on genetically-defined orphan diseases",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "03410790-fe9b-44c5-b91b-53f6b967df60",
      "evidence": "Central platform node connected to three strategic pillars",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}